Low Dose IL-2 Selective Treg Stimulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current IL-2 therapies for autoimmune and inflammatory diseases risk activating effector T cells, leading to undesirable immune responses and limited efficacy, as they primarily stimulate both regulatory and effector T lymphocytes, causing adverse effects and insufficient treatment outcomes.
Innovation Solution
Administering low doses of IL-2 to selectively stimulate regulatory T lymphocytes (Tregs) while minimizing the activation of effector T lymphocytes (Teffs), thereby shifting the Treg/Teff balance in favor of Tregs, reducing undesirable immune responses and associated side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If high doses of IL-2 are administered to stimulate regulatory T lymphocytes, then the Treg population increases, but effector T lymphocytes are also activated causing undesirable immune responses
Solution Approach 1:
The patent applies local quality by creating different IL-2 signaling environments for different T cell types. Low doses of IL-2 selectively stimulate Tregs through their high-affinity IL-2Rα receptor, while Teffs with lower-affinity receptors remain unactivated. This differential response based on receptor affinity creates localized selective stimulation without broad immune activation.
Solution Approach 2:
The patent changes the dosage parameter of IL-2 from high to low concentrations. This parameter change fundamentally alters which T cell populations are stimulated - low doses preferentially activate Tregs while sparing Teffs. The dosage parameter is the critical control point that resolves the contradiction between expanding Tregs and avoiding Teff activation.
2Reliability
If conventional IL-2 therapies are used for autoimmune diseases, then some immune response is stimulated, but the treatment lacks selectivity and causes side effects
Solution Approach 1:
The patent applies partial action by administering sub-threshold doses of IL-2 that are sufficient to stimulate Tregs but insufficient to activate Teffs. This partial stimulation achieves the desired immunomodulatory effect without reaching the excessive activation level that would cause harmful side effects. The low dose regime provides selective action with an improved safety profile.
3Ease of operation
If IL-2 is administered to treat autoimmune disorders, then regulatory T cells are stimulated, but effector T cells are also activated aggravating the disease
Solution Approach 1:
The patent changes the dosage parameter from conventional high doses to low doses of IL-2. This parameter modification transforms the therapeutic effect from non-selective immune stimulation to selective Treg activation. The low dose regime maintains treatment simplicity while avoiding disease aggravation through selective immunomodulation.
Data Source
AI summary
The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.